Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations
暂无分享,去创建一个
J. Noh | J. Yoon | Hye-Yeong Seong | H. Cheong | W. Kim | J. Song | M. Choi | June-Woo Lee | Eliel Nham | H. Hyun | Sun-Kyung Yoon | Se-Jin Park | Won-Seok Gwak | Byoung-Guk Kim
[1] J. Zahradník,et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant , 2023, bioRxiv.
[2] R. Arbel,et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study , 2023, The Lancet Infectious Diseases.
[3] Y. Choe,et al. Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study , 2023, Journal of Korean medical science.
[4] Man-Seong Park,et al. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection , 2023, Frontiers in Immunology.
[5] M. Kiso,et al. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1 , 2023, The Lancet Infectious Diseases.
[6] A. Tam,et al. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster , 2023, The Lancet Infectious Diseases.
[7] K. Joyal-Desmarais,et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022 , 2023, The Lancet Respiratory Medicine.
[8] Xiangxi Wang,et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5 , 2023, The Lancet Infectious Diseases.
[9] N. Kitchin,et al. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine , 2023, The New England journal of medicine.
[10] Bette Korber,et al. Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters , 2023, bioRxiv.
[11] J. Theiler,et al. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1 , 2023, The New England journal of medicine.
[12] Zahra A. Premji,et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression , 2023, The Lancet Infectious Diseases.
[13] J. Zahradník,et al. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant , 2023, bioRxiv.
[14] Peng Wang,et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution , 2022, bioRxiv.
[15] Xuping Xie,et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster , 2022, Nature Medicine.
[16] A. Gordon,et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants , 2022, Cell.
[17] S. Chakraborti,et al. Structural Profiles of SARS-CoV-2 Variants in India , 2022, Current Microbiology.
[18] Hafiz M.N. Iqbal,et al. Food Safety Control Measures to Address Emerging Omicron SARS-CoV-2 Variant of Concern , 2022, Journal of Pure and Applied Microbiology.
[19] M. Davenport,et al. Immune imprinting and SARS-CoV-2 vaccine design , 2021, Trends in Immunology.
[20] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[21] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[22] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[23] Ping Li,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .